Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease

Detalhes bibliográficos
Autor(a) principal: Périssé, André R. S.
Data de Publicação: 2013
Outros Autores: Smeaton, Laura, Chen, Yun, la Rosa, Alberto, Walawander, Ann, Nair, Apsara, Grinsztejn, Beatriz, Santos, Breno, Kanyama, Cecilia, Hakim, James, Nyirenda, Mulinda, Kumarasamy, Nagalingeswaran, Lalloo, Umesh G., Flanigan, Timothy, Campbell, Thomas B., Hughes, Michael D.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
DOI: 10.1371/journal.pone.0083643
Texto Completo: https://arca.fiocruz.br/handle/icict/31322
Resumo: P E A R L S study team of the ACTG.
id CRUZ_519716f736bcc5690ad5e9b88745a53f
oai_identifier_str oai:arca.fiocruz.br:icict/31322
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Périssé, André R. S.Smeaton, LauraChen, Yunla Rosa, AlbertoWalawander, AnnNair, ApsaraGrinsztejn, BeatrizSantos, BrenoKanyama, CeciliaHakim, JamesNyirenda, MulindaKumarasamy, NagalingeswaranLalloo, Umesh G.Flanigan, TimothyCampbell, Thomas B.Hughes, Michael D.2019-01-28T12:14:39Z2019-01-28T12:14:39Z2013PÉRISSÉ, André R. S. et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. Plos One, v. 8, n. 12, p. 1-7, Dec. 2013.1932-6203https://arca.fiocruz.br/handle/icict/3132210.1371/journal.pone.00836431932-6203P E A R L S study team of the ACTG.The project described was supported by Award Numbers UMAI068634 and UMAI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. Bristol Myers Squibb provided atazanavir, didanosine-EC and efavirenz (with consent of Merck); Gilead Sciences, Inc. provided emtricitabine, tenofovir-DF, emtricitabine/tenofovir-DF and financial support for purchase of other study drugs; GlaxoSmithKline provided lamivudine, zidovudine and lamivudine/zidovudine; and Boehringer Ingelheim Pharmaceuticals, Inc. provided nevirapine. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Employees of the NIAID participated as study team members and authors of this manuscript. The NIAID provided recommendations on the study design and approved the final study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. Bristol Myers Squibb, Gilead Sciences Inc., GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals, Inc. had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Representatives of the pharmaceutical company sponsors participated as study team members and authors of this manuscript, but did not participate in data collection, data analyses or interpretation.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Ciências Biológicas. Rio de Janeiro, RJ, Brasil.Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.Asociación Civil Impacta Salud y Educación. Lima, Peru.Frontier Science and Technology Research Foundation. Amherst, NY, USA.Frontier Science and Technology Research Foundation. Amherst, NY, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil,Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.Kamuzu Central Hospital. Lilongwe, Malawi.University of Zimbabwe College of Health Sciences. Harare, Zimbabwe.University of Malawi. College of Medicine. Blantyre, Malawi.YRG Centre for AIDS Research and Education. Chennai, India.Nelson R. Mandela School of Medicine. Durban, South Africa.Brown Medical School. Providence, RI, USA.University of Colorado. School of Medicine. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA.Harvard School of Public Health. Department of Biostatistics. Boston, MA, USA.Background: Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy (ART) with concurrent active TB or other AIDS-defining disease using data from the "Prospective Evaluation of Antiretrovirals in Resource-Limited Settings" (PEARLS) study. Methods: PARTICIPANTS WERE CATEGORIZED RETROSPECTIVELY INTO THREE GROUPS ACCORDING TO PRESENCE OF ACTIVE CONFIRMED OR PRESUMPTIVE DISEASE AT ART INITIATION: those with pulmonary and/or extrapulmonary TB ("TB" group), those with other non-TB AIDS-defining disease ("other disease"), or those without concurrent TB or other AIDS-defining disease ("no disease"). Primary outcome was time to the first of virologic failure, HIV disease progression or death. Since the groups differed in characteristics, proportional hazard models were used to compare the hazard of the primary outcome among study groups, adjusting for age, sex, country, screening CD4 count, baseline viral load and ART regimen. Results: 31 of 102 participants (30%) in the "TB" group, 11 of 56 (20%) in the "other disease" group, and 287 of 1413 (20%) in the "no disease" group experienced a primary outcome event (p = 0.042). This difference reflected higher mortality in the TB group: 15 (15%), 0 (0%) and 41 (3%) participants died, respectively (p<0.001). The adjusted hazard ratio comparing the "TB" and "no disease" groups was 1.39 (95% confidence interval: 0.93-2.10; p = 0.11) for the primary outcome and 3.41 (1.72-6.75; p<0.001) for death. Conclusions: Active TB at ART initiation was associated with increased risk of mortality in HIV-1 infected patients.engPublic Library of ScienceOutcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHIV-1Antiretroviral therapyTuberculosisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://arca.fiocruz.br/bitstreams/efe811af-85fc-42a8-9c57-9f61e24d8171/download586c046dcfeef936e32f0323bb9a47c0MD51falseAnonymousREADORIGINALOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdfOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdfapplication/pdf212600https://arca.fiocruz.br/bitstreams/da3d209c-2d1f-4913-aab3-33f58afd5584/downloadb7024d181f34e77325828e95b4132680MD52trueAnonymousREADTEXTOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdf.txtOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdf.txtExtracted texttext/plain38892https://arca.fiocruz.br/bitstreams/54b823a6-3cfc-4b71-be35-8c0b62675eb7/download20a9118ea3c14a607cf61b811e503b74MD511falseAnonymousREADTHUMBNAILOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdf.jpgOutcomes among HIV-1_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2013.pdf.jpgGenerated Thumbnailimage/jpeg6716https://arca.fiocruz.br/bitstreams/59ec747e-5fe5-4b46-a40a-884f891ad8fc/download1a00e58e9b5cb9a1da937fd409f83fb4MD512falseAnonymousREADicict/313222025-07-29 20:08:08.458open.accessoai:arca.fiocruz.br:icict/31322https://arca.fiocruz.brRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352025-07-29T23:08:08Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)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
dc.title.none.fl_str_mv Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
title Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
spellingShingle Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
Périssé, André R. S.
HIV-1
Antiretroviral therapy
Tuberculosis
title_short Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
title_full Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
title_fullStr Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
title_full_unstemmed Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
title_sort Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease
author Périssé, André R. S.
author_facet Périssé, André R. S.
Smeaton, Laura
Chen, Yun
la Rosa, Alberto
Walawander, Ann
Nair, Apsara
Grinsztejn, Beatriz
Santos, Breno
Kanyama, Cecilia
Hakim, James
Nyirenda, Mulinda
Kumarasamy, Nagalingeswaran
Lalloo, Umesh G.
Flanigan, Timothy
Campbell, Thomas B.
Hughes, Michael D.
author_role author
author2 Smeaton, Laura
Chen, Yun
la Rosa, Alberto
Walawander, Ann
Nair, Apsara
Grinsztejn, Beatriz
Santos, Breno
Kanyama, Cecilia
Hakim, James
Nyirenda, Mulinda
Kumarasamy, Nagalingeswaran
Lalloo, Umesh G.
Flanigan, Timothy
Campbell, Thomas B.
Hughes, Michael D.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Périssé, André R. S.
Smeaton, Laura
Chen, Yun
la Rosa, Alberto
Walawander, Ann
Nair, Apsara
Grinsztejn, Beatriz
Santos, Breno
Kanyama, Cecilia
Hakim, James
Nyirenda, Mulinda
Kumarasamy, Nagalingeswaran
Lalloo, Umesh G.
Flanigan, Timothy
Campbell, Thomas B.
Hughes, Michael D.
dc.subject.en.none.fl_str_mv HIV-1
Antiretroviral therapy
Tuberculosis
topic HIV-1
Antiretroviral therapy
Tuberculosis
description P E A R L S study team of the ACTG.
publishDate 2013
dc.date.issued.fl_str_mv 2013
dc.date.accessioned.fl_str_mv 2019-01-28T12:14:39Z
dc.date.available.fl_str_mv 2019-01-28T12:14:39Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv PÉRISSÉ, André R. S. et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. Plos One, v. 8, n. 12, p. 1-7, Dec. 2013.
dc.identifier.uri.fl_str_mv https://arca.fiocruz.br/handle/icict/31322
dc.identifier.issn.none.fl_str_mv 1932-6203
dc.identifier.doi.none.fl_str_mv 10.1371/journal.pone.0083643
dc.identifier.eissn.none.fl_str_mv 1932-6203
identifier_str_mv PÉRISSÉ, André R. S. et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. Plos One, v. 8, n. 12, p. 1-7, Dec. 2013.
1932-6203
10.1371/journal.pone.0083643
url https://arca.fiocruz.br/handle/icict/31322
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://arca.fiocruz.br/bitstreams/efe811af-85fc-42a8-9c57-9f61e24d8171/download
https://arca.fiocruz.br/bitstreams/da3d209c-2d1f-4913-aab3-33f58afd5584/download
https://arca.fiocruz.br/bitstreams/54b823a6-3cfc-4b71-be35-8c0b62675eb7/download
https://arca.fiocruz.br/bitstreams/59ec747e-5fe5-4b46-a40a-884f891ad8fc/download
bitstream.checksum.fl_str_mv 586c046dcfeef936e32f0323bb9a47c0
b7024d181f34e77325828e95b4132680
20a9118ea3c14a607cf61b811e503b74
1a00e58e9b5cb9a1da937fd409f83fb4
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1839715954334892032

Registros relacionados